Clinical medicine

In-Person Testing and Signature Requirements Waived for Home Oxygen Needs

Thursday, April 2, 2020 - 4:52pm

The latest rules, issued March 30, waive the in-person testing and signature for delivery requirements for supplemental oxygen.

Key Points: 
  • The latest rules, issued March 30, waive the in-person testing and signature for delivery requirements for supplemental oxygen.
  • The groups requested that, given the current global health pandemic, CMS waive all in-person testing requirements for patients receiving supplemental oxygen for the first time, as well as for patients who require recertification for oxygen prescriptions.
  • The groups also urged CMS to waive the requirement for signature at delivery of supplemental oxygen.
  • Many PF patients require supplemental oxygen in order to survive, and in-person testing for supplemental oxygen or signing for delivery of supplemental oxygen could expose at-risk patients to the virus.

Global Transcatheter Aortic Valve Replacement (TAVR) Market: Size, Trends and Forecasts (2020-2024) - ResearchAndMarkets.com

Thursday, April 2, 2020 - 5:00pm

2.4 Transcatheter Aortic Valve Replacement (TAVR) Segmentation: An Overview

Key Points: 
  • 2.4 Transcatheter Aortic Valve Replacement (TAVR) Segmentation: An Overview
    3.1.3 Global TAVR Market by Procedure (Transfemoral Implantation, Transapical Implantation, and Transaortic Implantation)
    3.1.4 Global TAVR Market by Region (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
    3.1.5 Global TAVR Market Volume by Region (The US, China, and ROW)
    4.1 North America TAVR Market: An Analysis
    4.3 Asia Pacific TAVR Market: An Analysis
    4.4 Middle East & Africa TAVR Market: An Analysis
    4.5 Latin America TAVR Market: An Analysis

Health Canada Grants Emergency Use Authorization for N8 Medical CeraShield™ Endotracheal Tubes in Mechanically Ventilated COVID-19 Patients

Thursday, April 2, 2020 - 2:55pm

DUBLIN, Ohio, April 2, 2020 /PRNewswire/ --N8 Medical, LLC (N8 Medical) today announced that Health Canada has granted Dr. John Muscedere of Kingston General Hospital's emergency request to begin using the N8 Medical CeraShield Endotracheal Tubes in mechanically-ventilated COVID-19 patients.

Key Points: 
  • DUBLIN, Ohio, April 2, 2020 /PRNewswire/ --N8 Medical, LLC (N8 Medical) today announced that Health Canada has granted Dr. John Muscedere of Kingston General Hospital's emergency request to begin using the N8 Medical CeraShield Endotracheal Tubes in mechanically-ventilated COVID-19 patients.
  • N8 Medical's CeraShield Endotracheal Tube has a patented anti-fouling coating that is designed to prevent deadly bacterial infections that frequently occur in ventilated patients with respiratory viral infections.
  • N8 Medical believes that use of the CeraShield Endotracheal Tube may reduce this rate of mortality.
  • Dr. Muscedere was the Principal Investigator in a clinical feasibility study of the CeraShield Endotracheal Tube of ten patients at Kingston General who were intubated with the CeraShield Endotracheal Tube.

Seed of hope: COVID-19 vaccine trials begin

Thursday, April 2, 2020 - 2:00pm

Once proves effective after three phases of clinical trials, the vaccine is expected to be available for the public in as little as six months' time.

Key Points: 
  • Once proves effective after three phases of clinical trials, the vaccine is expected to be available for the public in as little as six months' time.
  • Having previously traveled to Sierra Leone during the Ebola outbreak, she developed China's first homegrown vaccine for the virus, making China the third country to put an Ebola vaccine into clinical trials.
  • After two months of hard work, they developed the recombinant novel coronavirus vaccine, using the same technology as was used for the Ebola vaccine.
  • The COVID-19 vaccine is a seed of hope for humanity, and one which is showing positive signs.

New Study Shows Benefit of Using Signatera™ Technology for Personalized Monitoring in Gastrointestinal Cancer

Thursday, April 2, 2020 - 2:15pm

This report builds upon a fast-growing body of scientific evidence behind the Signatera test across multiple cancer types.

Key Points: 
  • This report builds upon a fast-growing body of scientific evidence behind the Signatera test across multiple cancer types.
  • The study follows a 72-year old man with recurrent Stage III esophageal cancer whose recurrence was detected 350 days before radiographic imaging, using Signatera's personalized and tumor-informed technology.
  • Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer.
  • Signatera test performance has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers.

Global Salicylic Acid Market (2020 to 2025) - Growth, Trends and Forecasts - ResearchAndMarkets.com

Thursday, April 2, 2020 - 2:37pm

The "Salicylic Acid Market - Growth, Trends and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Salicylic Acid Market - Growth, Trends and Forecasts (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering.
  • Global salicylic acid market is projected to register a CAGR of 4.8% during the forecast period 2020-2025.
  • Moreover, the growing demand for dermatological treatment products such as acne solutions across the globe drives the market for premium salicylic acid.
  • Owing to the robust production and largest export of salicylic acid in the country, China poses high power in regulating global ingredient price

2020 Insights into Medical Device Technologies for Non-Invasive, Drug Free Pain Management - ResearchAndMarkets.com

Thursday, April 2, 2020 - 2:08pm

The "Breakthrough Medical Device Technologies for Non-Invasive, Drug Free Pain Management" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Breakthrough Medical Device Technologies for Non-Invasive, Drug Free Pain Management" report has been added to ResearchAndMarkets.com's offering.
  • Medtech developers have been trying to come up with innovative non-drug based pain management therapies for the past several years.
  • The research service covers a snapshot of key non-invasive, non-drug medical devices for pain management.
  • The research service also throws light on the key growth opportunities in the field of non-invasive, non-drug pain management devices market.

Tablo® Hemodialysis System Receives FDA Clearance for Home Dialysis

Thursday, April 2, 2020 - 1:30pm

Currently, more than 500,000 Americans undergo dialysis treatments three or more times each week, typically lasting four hours per treatment.

Key Points: 
  • Currently, more than 500,000 Americans undergo dialysis treatments three or more times each week, typically lasting four hours per treatment.
  • A prospective, multicenter, home hemodialysis trial with 30 patients was completed in 2019 and confirmed the Tablo system is safe and effective for home use.
  • Over the years, he has had thousands of dialysis treatments at various centers as well as on home hemodialysis.
  • Requiring only an electrical outlet and tap water to operate, the mobile Tablo system frees patients and providers from expensive clinic infrastructure.

NanoMosaic Announces Exclusive License to Nanoneedle Technology from Harvard

Thursday, April 2, 2020 - 1:00pm

announced today it is commercializing technology for high-throughput, high-sensitivity analyte detection initially developed at Harvard University, through an exclusive license agreement with Harvard Office of Technology Development.

Key Points: 
  • announced today it is commercializing technology for high-throughput, high-sensitivity analyte detection initially developed at Harvard University, through an exclusive license agreement with Harvard Office of Technology Development.
  • The platform technology has high multiplex capabilities with simple label-free reactions, enabling biomarker discovery and validation on a single chip.
  • The nanoneedle technology was developed in Quan's lab while he was a Junior Fellow at Harvard's Rowland Institute.
  • The fund's current portfolio focuses on technology platforms as well as technology derived products and assets across the genomics, proteomics, diagnostics, drug discovery and therapeutics spaces.

Hope4Cancer™ Treatment Centers To Launch 'Eight Days,' A Novel Reality Show About Alternative Ways To Fight Cancer

Thursday, April 2, 2020 - 1:00pm

Hope4Cancer Treatment Centers announces Eight Days, a groundbreaking reality TV series that tells the stories of five cancer survivors and their journey using integrative cancer treatments that are working.

Key Points: 
  • Hope4Cancer Treatment Centers announces Eight Days, a groundbreaking reality TV series that tells the stories of five cancer survivors and their journey using integrative cancer treatments that are working.
  • The first reality TV series of its kind,Eight Days,is set to premiere on the WGN Network, on Sunday, April 5, 2020.
  • From physical, emotional, and spiritual healing, as well as, how to treat the root of cancer instead of the symptoms.
  • But being a parent, I've taken the gloves off, and I'm ready to fight this," says Kate Malvenan, cancer patient, Eight Days.